VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewsWire • 03/19/24
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 03/13/24
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateGlobeNewsWire • 02/29/24
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumGlobeNewsWire • 02/27/24
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/21/24
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)Benzinga • 01/16/24
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of VitiligoGlobeNewsWire • 01/10/24
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of DirectorsGlobeNewsWire • 01/03/24
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/13/23
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/02/23
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 MillionGlobeNewsWire • 11/01/23
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202GlobeNewsWire • 10/30/23
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental VitiligoGlobeNewsWire • 10/30/23
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2%Zacks Investment Research • 08/17/23
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/23
Can VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 05/17/23
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/23
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory ConditionsGlobeNewsWire • 05/01/23